Caladrius Biosciences Closes The Sale Of Its Remaining Interest In PCT To Hitachi Chemical Co., Ltd. For $75 Million Post author:Sam Post published:May 18, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like MabVax CEO Looks for Potential Deals at JPM to Support its Human Antibody Programs January 9, 2018 Dicerna Could Pocket $201M in NASH R&D Deal With Boehringer Ingelheim November 1, 2017 AbbVie Declares Quarterly Dividend February 19, 2017